FDG PET-CT imaging in assessing interim response to neoadjuvant cisplatin-based chemotherapy (NAC) in muscle invasive bladder cancer (MIBC): A prospective study.

被引：0
|
作者：
Sridhar, Srikala S.
Power, Nicholas
Breau, Rodney H.
Cheng, Susanna Y.
Pond, Gregory Russell
Chung, Peter W. M.
Metser, Ur
Levine, Mark Norman
Mukherjee, Som D.
机构：
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] London Hlth Sci Ctr, London, ON, Canada
[3] Ottawa Hosp, Ottawa, ON, Canada
[4] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada
[5] McMaster Univ, Ontario Clin Oncol Grp, Hamilton, ON, Canada
[6] Univ Hlth Network, Radiat Med Program, Princess Margaret Canc Ctr, Toronto, ON, Canada
[7] Princess Margaret Hosp, Toronto, ON, Canada
[8] Ontario Clin Oncol Grp, Hamilton, ON, Canada
[9] McMaster Univ, Dept Oncol, Juravinski Canc Ctr, Hamilton, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
460
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Predictors of complete pathological response (pT0) to neoadjuvant chemotherapy (NAC) in muscle-invasive bladder carcinoma (MIBC)
    Pokuri, Venkata Kiran
    Syed, Johar R.
    Yang, Zhengyu
    Field, Erinn P.
    Pill, Roberto
    Levine, Ellis Glenn
    Trump, Donald L.
    Hutson, Alan
    Guru, Khurshld
    George, Saby
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] Predictors of complete pathological response (pT0) to neoadjuvant chemotherapy (NAC) in muscle-invasive bladder carcinoma (MIBC)
    Pokuri, Venkata Kiran
    Syed, Johar R.
    Yang, Zhengyu
    Field, Erinn P.
    Cyriac, Susanna
    Azabdaftari, Gissou
    Pili, Roberto
    Levine, Ellis Glenn
    Trump, Donald L.
    Hutson, Alan
    Guru, Khurshid
    George, Saby
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] Neoadjuvant cisplatin-based chemotherapy followed by selective bladder preservation chemoradiotherapy (CRT) in muscle-invasive urothelial carcinoma of bladder (MIBC): A combined retrospective analysis of two prospective studies.
    Hong, Joohyun
    Choi, Daeho
    Sung, Hyun Hwan
    Jeong, Byong Chang
    Park, Se Hoon
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [34] Safety and efficacy of neoadjuvant chemotherapy (NAC) with accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (aMVAC) in patients (pts) with muscle invasive bladder cancer (MIBC) as a function of age
    Zibelman, Matthew R.
    Lewis, Bianca
    Ross, Eric A.
    Anari, Fern
    Ghatalia, Pooja
    Plimack, Elizabeth R.
    Geynisman, Daniel M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [35] Predictive value of phenotypic signatures of bladder cancer response to cisplatin-based neoadjuvant chemotherapy
    Hensley, Patrick J.
    Kyprianou, Natasha
    Purdom, Matthew S.
    He, Daheng
    DiCarlo, Vincent
    Wang, Chi
    James, Andrew C.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (09) : 572.e1 - 572.e11
  • [36] Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer
    Gil Jimenez, Albert
    van Dorp, Jeroen
    Contreras-Sanz, Alberto
    van der Vos, Kristan
    Vis, Daniel J.
    Braaf, Linde
    Broeks, Annegien
    Kerkhoven, Ron
    van Kessel, Kim E. M.
    Ribal, Maria Jose
    Alcaraz, Antonio
    Wessels, Lodewyk F. A.
    Seiler, Roland
    Wright, Jonathan L.
    Mengual, Lourdes
    Boormans, Joost
    van Rhijn, Bas W. G.
    Black, Peter C.
    van der Heijden, Michiel S.
    EUROPEAN UROLOGY, 2023, 83 (04) : 313 - 317
  • [37] IDENTIFICATION OF MOLECULAR BIOMARKERS OF CISPLATIN-BASED CHEMOSENSITIVITY IN PATIENTS UNDERGOING NEOADJUVANT CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER
    Shah, Paras
    Kozel, Zachary
    Lee, Annette
    Korsunsky, Ilya
    Shih, Andrew
    Yaskiv, Oksana
    Vira, Manish
    Bradley, Thomas
    Zhu, Xinhua
    JOURNAL OF UROLOGY, 2017, 197 (04): : E1196 - E1197
  • [38] Pathological TO Following Cisplatin-Based Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Network Meta-analysis
    Kim, Hyung Suk
    Jeong, Chang Wook
    Kwak, Cheol
    Kim, Hyeon Hoe
    Ku, Ja Hyeon
    CLINICAL CANCER RESEARCH, 2016, 22 (05) : 1086 - 1094
  • [39] Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer
    Osterman, Chelsea K.
    Babu, Dilip S.
    Geynisman, Daniel M.
    Lewis, Bianca
    Somer, Robert A.
    Balar, Arjun V.
    Zibelman, Matthew R.
    Guancial, Elizabeth A.
    Antinori, Gianna
    Yu, Shun
    Narayan, Vivek
    Guzzo, Thomas J.
    Plimack, Elizabeth R.
    Vaughn, David J.
    Fung, Chunkit
    Mamtani, Ronac
    ONCOLOGIST, 2019, 24 (05): : 688 - 690
  • [40] A phase 3 randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) ± BMS-986205 in cisplatin-eligible muscle invasive bladder cancer (MIBC).
    Sonpavde, Guru
    Necchi, Andrea
    Gupta, Shilpa
    Steinberg, Gary D.
    Gschwend, Juergen E.
    Van der Heijden, Michiel Simon
    Garzon, Nathalie
    Elegbe, Ayanbola
    Raybold, Bradley
    Liaw, Danny
    Rutstein, Mark
    Galsky, Matt D.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345